From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia

From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia

Abstract Cancer cells utilize the main de novo pathway and the alternative salvage pathway for deoxyribonucleotide biosynthesis to achieve adequate nucleotide pools. Deoxycytidine kinase is the rate-limiting enzyme of the salvage pathway and it has recently emerged as a target for anti-proliferative...

Full description

Bibliographic Details
Main Authors: Magali Saez-Ayala, Laurent Hoffer, Sébastien Abel, Khaoula Ben Yaala, Benoit Sicard, Guillaume P. Andrieu, Mehdi Latiri, Emma K. Davison, Marco A. Ciufolini, Paul Brémond, Etienne Rebuffet, Philippe Roche, Carine Derviaux, Edwige Voisset, Camille Montersino, Remy Castellano, Yves Collette, Vahid Asnafi, Stéphane Betzi, Patrice Dubreuil, Sébastien Combes, Xavier Morelli
Format: Article
Language:English
Published: Nature Portfolio 2023-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-38668-2

Internet

https://doi.org/10.1038/s41467-023-38668-2

Similar Items